Sentences with phrase «overall survival rate»

Overall survival rate in dogs with heat stroke is approximately 50 %.

The median overall survival was 12.5 months, and the 12 - month overall survival rate was 58 %.

While there have been improvements in the current standard treatments, patients with glioblastoma (GBM), the most common and aggressive form of brain tumor, still suffer from a median survival rate of only 14.6 months and 5 - year overall survival rates of less than 10 %.

[2] While the 5 - year overall survival rate for cutaneous melanoma is 80 %, the rate for mucosal melanoma is only 25 %.

[17,20] The 5 - year overall survival rate for mucosal melanoma of the head and neck ranges from 17 % to 35 %.

At five - years post-treatment, patients in the HFX arm had the highest overall survival rates at 37.1 percent (HR 0.81, 95 percent CI), compared to 33.7 percent for the AFX - C arm, 29.3 percent for the SFX arm, 29.0 percent for the AFX - S arm.

The drug lenvatinib can significantly improve overall survival rates in a group of thyroid cancer patients whose disease is resistant to standard radioiodine treatment, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

Patients who had surgery in sunny months — May to August — had a roughly 30 percent higher overall survival rate or time to cancer recurrence than did those getting surgery in the winter.

Further, they conducted multiple analyses to compare overall survival rates, disease - free survival rates, and melanoma specific survival rates of pregnant women to their non-pregnant counterparts diagnosed with melanoma.

A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen), showed that a new drug called MM - 398, given in combination with 5 - flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously - treated pancreatic cancer.

The median overall survival rate of 16.5 months exceeds the historical average survival of six - 12 months with standard chemotherapy.

To look at farming's impact on overall survival rates, marine biologists Jennifer Ford and the late Ransom Myers of Dalhousie University in Halifax, Nova Scotia, examined three decades» worth of data from Ireland, Scotland, and Canada.

Landmark overall survival rates at two and three years (OS24, OS36) were 34.8 % and 26.1 % respectively.

Results of the randomized trial reported that although the 2 - year failure - free survival rates with transplant were higher (71 % vs. 62 %), overall survival was not significantly changed in 5 - year overall survival rates between the groups of participants who underwent transplant.

Patients with untreated metastatic disease have a five - year overall survival rate of less than 10 percent.

[25,28,29] The 5 - year overall survival rate for vulvovaginal melanoma is 36 %, with better outcomes for vulvar melanoma than vaginal melanoma.

[33] Anorectal melanomas tend to have a poor prognosis, with a 5 - year overall survival rate of approximately 20 %.

The 3 - month overall survival rate was 65 % for nivolumab monotherapy and 64 % for the combination.

In fact, survival rates could be as different as more than 80 percent for the incubated startups as opposed to the overall survival rate of about 20 percent for all startups.

In fact, a recent trial showed that ipilimumab does not improve the overall survival rate of men with prostate cancer.

St. Jude is working to drive the overall survival rate for childhood cancer to 90 percent, and we won't stop until no child dies from cancer.

Importantly, analyses of overall survival rates and melanoma - specific survival rates for pregnancy - associated melanomas versus non-pregnancy-associated melanomas in stages 0 to III melanoma showed no differences (due to the lack of patients with stage IV melanoma, those patients were excluded from the analyses).

Initial remission rates for T - ALL with current treatments are about 90 percent, but the overall survival rate is between 60 and 70 percent.

«The 2 - year overall survival rate of these responder patients was 100 percent, whereas the rate for non-responders was just 25 percent,» Tanyi said.

In absolute terms, the overall survival rate at five years was 11 % higher in the ipilimumab arm (65 %) than in the placebo arm (54 %).

The 10 - year and 15 - year overall survival rates were 68.4 and 50.3 percent for intermediate - risk patients compared to 83.6 percent and 68.8 percent for low - risk patients.

The five year disease - free and overall survival rates for patients with high - risk malignant germ cell tumours remains less than 50 %, and so accurate diagnosis and monitoring is crucial to improving outcomes for patients.

Their study, published in Cancer Research, reveals that the gene NPTX2, plays an essential role in this cancer type, which is resistant to common chemotherapy and has a five - year overall survival rate of less than 10 percent in patients with metastatic disease.

In the total patient population, the 5 - year overall survival rate was 95 %, although it was significantly higher in non-cirrhotic (97 %) than cirrhotic patients (92 %).

Little is known about how CNS - PNETs develop, although these tumors are more aggressive than other PNETs and have an overall survival rate of only about 20 percent.

The 10 - year overall survival rates were 51.8 % (CI 47.0 - 56.4) for the patients receiving adjuvant chemotherapy and 48.4 % (95 % CI 43.6 - 53.0 %) for those in the surveillance groups (HR = 0.91, 95 % CI 0.77 - 1.09, p = 0.32).

While younger patients have a better prognosis, overall survival rates are very poor and new treatments are needed.

Babies in the study who were born at 22 weeks gestational age had an overall survival rate of 5.1 percent and a survival without severe impairment rate of 3.4 percent.

The study babies who were born at 26 weeks had an overall survival rate of 81.4 percent and a survival without severe impairment rate of 75.6 percent.

There was also a statistically significant absolute 10.3 percent improvement in the 5 - year overall survival rate (20.7 percent vs. 10.4 percent) and a 4.5 percent improvement in the 10 - year survival rate (12.2 percent vs. 7.7 percent), compared with observation alone.

From 2004 to 2012 — the years in which adoption of SBRT in community practice became widespread — the overall survival rate at 23 months following SBRT alone rose nearly 20 percentage points, from 39 to 58 percent (p < 0.001).

For this interim analysis, Hellmann described the 3 - month progression - free and overall survival rates.

The overall survival rate for all patients fell from about 63 percent after 12 months to a little over one - third after four years, and then plateaued.

Patients on both arms had an overall survival rate greater than 80 % (80.6 % for four vs 87.5 % for five courses), suggesting «the salvageability of patients following relapse,» Getz said.

The 2 - year progression - free and overall survival rates were 26.4 % and 56.6 % for patients with histone modifier gene mutations and 49.6 % and 63.3 % for patients without mutations (Figure 2A, B).

For the 411 melanoma patients enrolled, the 1 - year overall survival rate was 69 %.

For the 411 melanoma patients enrolled in the trial, the 1 - year overall survival rate was 69 % — almost three times better than with standard therapy.

In this trial, which is being led by CRI's clinical director Jedd Wolchok, M.D., Ph.D., the 2 - year overall survival rate for all dose cohorts was 79 %.

While the incidence of childhood cancer has changed only slightly since Candlelighters inception in 1970 (an increase from 11.4 per 100,000 population in 1974 to 14.8 per 100,000 in 2004), the overall survival rate for childhood cancer has increased drastically during that time period.